Compare · CHFS vs OM
CHFS vs OM
Side-by-side comparison of CHF Solutions, Inc. (CHFS) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CHFS and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- OM carries a market cap of $1.64B.
- OM has hit the wire 6 times in the past 4 weeks while CHFS has been quiet.
- OM has more recent analyst coverage (13 ratings vs 0 for CHFS).
- Company
- CHF Solutions, Inc.
- Outset Medical Inc.
- Price
- -
- $4.53-0.88%
- Market cap
- -
- $1.64B
- 1M return
- -
- +28.37%
- 1Y return
- -
- -61.13%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 0
- 13
OM
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest CHFS
- Nuwellis to Advance Treatment of Critically-Ill Children and Babies Under $1.7 Million NIH Grant
- Nuwellis, Inc. To Announce Second Quarter 2021 Financial Results on August 10, 2021
- American Medical Association Issues New CPT Code for Nuwellis' Aquadex Ultrafiltration
- Nuwellis Announces New Appointments to Leadership Team
- Nationwide Access to Ultrafiltration Therapy Possible with Nuwellis and Premier, Inc. Collaboration
- ACC 2021 Presentation Adds to Body of Evidence Supporting Nuwellis Ultrafiltration to Treat Patients with Heart Failure
- Nuwellis, Inc. Announces 18 Percent Increase in Revenue for First Quarter 2021 Over Previous Year and Provides Company Update
- Nuwellis, Inc. To Announce First Quarter 2021 Financial Results on May 11, 2021
- CHF Solutions Expands Commercial Focus, Changes Name to Nuwellis
- CHF Solutions, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
Latest OM
- SEC Form DEFA14A filed by Outset Medical Inc.
- SEC Form DEF 14A filed by Outset Medical Inc.
- SEC Form 4 filed by Elliott Derick A.
- SEC Form 3 filed by new insider Elliott Derick A.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Outset Medical Names Derick Elliott as Executive Vice President of Commercial
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Amendment: New insider Leonard Braden Michael claimed ownership of 1,902,201 shares (SEC Form 3)
- General Counsel Brottem John L. sold $9,521 worth of shares (2,842 units at $3.35), decreasing direct ownership by 8% to 32,935 units (SEC Form 4)
- Chair and CEO Trigg Leslie sold $11,259 worth of shares (3,361 units at $3.35), decreasing direct ownership by 3% to 102,342 units (SEC Form 4)